Trials / Completed
CompletedNCT05509634
Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors
Compared With Fosaprepitant Dimeglumine for Injection and Palonosetron Hydrochloride Injection, to Evaluate the Efficacy and Safety of HR20013 for Injection for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 754 (actual)
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of HR20013 for injection for prevention of chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HR20013 for injection；dexamethasone | HR20013 for injection；Drug for preventing nausea and vomiting caused by chemotherapy dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy |
| DRUG | fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone | fosaprepitant dimeglumine for injection: Drug for preventing nausea and vomiting caused by chemotherapy palonosetron hydrochloride injection: Drug for preventing nausea and vomiting caused by chemotherapy dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy |
Timeline
- Start date
- 2022-09-21
- Primary completion
- 2023-06-19
- Completion
- 2023-08-30
- First posted
- 2022-08-22
- Last updated
- 2023-10-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05509634. Inclusion in this directory is not an endorsement.